Genocea Biosciences (NASDAQ:GNCA) Trading 7.7% Higher

Genocea Biosciences Inc (NASDAQ:GNCA)’s share price traded up 7.7% during trading on Tuesday . The company traded as high as $2.43 and last traded at $2.37, 142,038 shares traded hands during mid-day trading. A decline of 7% from the average session volume of 153,289 shares. The stock had previously closed at $2.20.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a report on Thursday, October 24th. HC Wainwright reaffirmed a “buy” rating on shares of Genocea Biosciences in a report on Monday, November 11th. Leerink Swann started coverage on shares of Genocea Biosciences in a report on Friday, November 15th. They issued an “outperform” rating for the company. Finally, Svb Leerink started coverage on shares of Genocea Biosciences in a report on Friday, November 15th. They set an “outperform” rating and a $7.00 price target for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.94.

The company has a market cap of $57.53 million, a price-to-earnings ratio of -0.64 and a beta of 2.32. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.33 and a quick ratio of 4.33. The firm’s fifty day moving average price is $2.21 and its 200-day moving average price is $2.86.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.17. As a group, equities analysts forecast that Genocea Biosciences Inc will post -1.77 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley acquired a new position in shares of Genocea Biosciences during the second quarter valued at $26,000. Cubist Systematic Strategies LLC acquired a new position in shares of Genocea Biosciences during the second quarter valued at $40,000. Citadel Advisors LLC acquired a new position in shares of Genocea Biosciences during the second quarter valued at $68,000. D. E. Shaw & Co. Inc. acquired a new position in shares of Genocea Biosciences during the second quarter valued at $84,000. Finally, DRW Securities LLC acquired a new position in shares of Genocea Biosciences during the second quarter valued at $118,000. 54.93% of the stock is owned by institutional investors.

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Further Reading: What is a recession?

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.